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Supplementary Methods 
1. UK Biobank data 
The UK Biobank cohort includes ~500,000 volunteers aged 40-69 years of age ascertained through 
NHS registers
1
. Following informed consent participants completed a standardised questionnaire on 
life course exposures, medical history and treatments and underwent a standardised portfolio of 
phenotypic tests including two blood pressure measurements taken seated after two minutes rest 
using an appropriate cuff and an Omron HEM-7015IT digital blood pressure monitor. Body mass 
index (BMI) was calculated as weight (kg) divided by height squared (m
2
) with weight measured 
using an electronic weighing scales (Tanita BC-418). The participants undergo longitudinal life course 
linkage to electronic health data including Hospital Episode Statistics and Office for National 
Statistics cause of death data. 
The UK Biobank and UK BiLEVE genotyping arrays overlap with over 95% of SNVs content in 
common. These customised chips were designed to give genome-wide coverage of SNVs, including 
some insertion deletion polymorphisms (indels) and include validated exome content from the first 
55K participants in the UK exome chip study. With approved access to the full genetic data, a total of 
~73 million autosomal genetic variants were available for analysis, of which ~9.8 million SNVs with 
minor allele frequency (MAF) >1% and imputation quality INFO > 0.1 are analysed here for GWAS. 
2. Quality Control 
All SNVs had passed central Quality Control (QC) checks, such as tests of Hardy-Weinberg 
Equilibrium, batch and plate effects, multi-allelic SNVs and poorly called SNVs. The SNVs which failed 
QC were set to missing for all individuals in the corresponding batch within the final genetic data 
files provided. Likewise, the QC performed centrally for each sample tested for heterozygosity and 
missing rates. Samples were further investigated for relatedness and Principal Components Analysis 
(PCA) was performed. Full details of the QC of the genetic data performed centrally by UK Biobank 
are available
2
.  
We performed additional QC of the genetic data, using QC files provided by UK Biobank. Variants 
were excluded according to two lists provided by UK Biobank: (i) 417 SNVs with discordant results 
between the two 1000 Genomes control samples added to each plate; (ii) 65 SNVs which were later 
found by UK Biobank to be discordant. Samples were excluded after application of basic QC filters 
following the central QC tests: (i) N=480 individuals indicated in the data, which were recommended 
for exclusion due to high missingness or heterozygosity rates; (ii) N=459 individuals flagged as QC 
failures from UK BiLEVE; (iii) N=191 individuals whose phenotypic sex differs from the genetically 
inferred sex. 
We restricted our data to a subset of unrelated European ancestry individuals for analysis. First, we 
selected European ancestry individuals using the Principal Component (PC) results from the centrally 
generated PCA, which included the first 15 PCs for all ~150k samples. We performed a 4-means 
clustering according to each of PC1 and PC2 separately using the kmeans algorithm in R statistical 
software, corresponding to four ethnic groups (White, Black, Asian, Chinese) and created an 
intersection of these two clusterings, to create five final clusters (White, Black, Asian, Chinese, 
Mixed/Other) (Supplementary Fig. 15). We selected individuals corresponding to the White cluster, 
and further removed any remaining individuals with self-reported mixed ethnicity. A total of 
N=145,315 Europeans remained in the data for further QC. We note that this is larger than the 
subset of 120,286 individuals which UK Biobank classified as being ͞pƌoďaďle CauĐasiaŶs aŵoŶgst 
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people who self-ideŶtified as Bƌitish͟ aŶd used as a hoŵogeŶeous EuƌopeaŶ aŶĐestƌǇ saŵple foƌ 
variant QC
2
, as stricter homogeneity is required for QC than for analysis. 
Furthermore, we used the results of the central UK Biobank kinship analyses, which provided kinship 
coefficients and IBS0 estimates. We identified pairs of related samples and restricted the data to a 
set of unrelated individuals, by removing the individual with highest missingness rate within any pair 
of twins, 1
st
 or 2
nd
 degree relatives. Overall a total of N=141,647 unrelated European ancestry 
individuals remained post-QC. 
3. Phenotypic data 
In parallel, the phenotypic data were also considered for QC. In order to calculate the mean of the 
two blood pressure (BP) measurements, we restricted the data to individuals with both 
measurements available. From the full original dataset, this led to the exclusion of N=142 individuals 
with missing data for both 1
st
 and 2
nd
 BP readings, and N=139 / N=135 with only 1 of the 2 
measurements available for systolic BP (SBP) / diastolic BP (DBP) respectively, as well as the 
exclusion of N=95 individuals who only had BP measurements from a manual sphygmomanometer. 
Individuals with missing covariates were removed from the data, hence excluding N=324 individuals 
with missing BMI. Furthermore we excluded N=35 pregnant women. These phenotypic sample 
exclusions were applied to all individuals who had passed the above genetic QC. Following both 
genetic and phenotypic data QC, the sample size for analysis therefore included N=140,882 and 
N=140,886 unrelated European ancestry individuals for SBP and DBP, respectively. 
Analysis of the summary descriptive statistics of the UK Biobank sample (Supplementary Table 1) 
shows there were small but significant differences when comparing the UK Biobank vs UK BiLEVE 
participants, for age and BMI, due to large sample sizes. UK BiLEVE participants were slightly older 
and heavier compared to the UK Biobank participants. Moreover males and females were equally 
represented in the UK BiLEVE sample whereas more females (54.3%) were included in UK Biobank 
data. 
4. Linkage Disequilibrium calculations 
Linkage Disequilibrium (LD) was calculated between sets of variants within the full genetic dataset 
using PLINK software
3
. In order to do this, all genetic data were converted from BGEN format to 
PLINK binary format. For any given SNV for which LD calculations were performed, the LD was 
estimated for all variants within a 500kb window downstream and upstream of this reference SNV. 
All variants in LD with the reference SNV reaching an r
2
 ш Ϭ.Ϯ thƌeshold ǁeƌe ideŶtified.  
5. Exome variants 
Considering all 247,870 SNVs from the exome chip (Illumina HumanExome BeadChip arrays) 
annotation file, we searched for all 241,561 autosomal SNVs from the polymorphic SNVs within our 
data. There were 149,325 SNVs covered directly, and a further 486 exome chip SNVs were covered 
by proxies (r
2
 > 0.7) according to LD from the 1000G reference data set (phase3 v5a.20130502 and 
phase1 v3.20101123), giving a total of 149,811 SNVs to consider. All SNVs are directly genotyped on 
the exome chip within the two exome replication datasets. 
5 
 
6. Post-results Quality Control (QC) 
We undertook further QC checks for any potential outliers. The additional QC included plots 
comparing trends between Minor Allele Frequency (MAF), Standard Error (SE), betas and P-values, 
Quantile-Quantile plots (Supplementary Fig. 16) with and without exclusion of known-LD variants 
(all variants in LD with previously reported variants at the time of analysis), and the corresponding 
lambda values for genomic inflation were also calculated. After inspection of our QQ-plots, we 
applied the LD score regression approach
4
 to determine whether any inflation was due to 
polygenicity or underlying population stratification. In particular, inspection and comparison of such 
plots enabled the selection of the optimal threshold for MAF and INFO filters, where INFO is the 
imputation quality score output from SNPTEST. We applied a post-analysis filter using an INFO 
threshold of 0.1, to exclude SNVs with low imputation quality from our results. Inspection of the 
plots from UKB documentation
5
 shows that imputation quality is high for SNVs with MAF ш 1%, and 
aŶǇ “NVs ǁith INFO ч Ϭ.ϭ aƌe ŵostlǇ ƌaƌe “NVs. Note that aŶ INFO thƌeshold of Ϭ.ϭ is lower than 
previously used in smaller GWAS, but appears suitable due to the much larger sample size and high 
statistical power in UK Biobank
5
. Furthermore, our validated findings all have good imputation 
quality. 
For the UK Biobank exome discovery, there were 149,026 Exome SNVs which were polymorphic with 
INFO > 0.1. Inspection of QC diagnostic plots specifically for these SNVs alone suggested an optimal 
MAF filter of 0.01%, thus excluding rare variant outliers with large beta and SE values. This gave 
114,641 remaining SNVs. In keeping with other exome-based studies of rare variants, we chose a 
less stringent P-value threshold for these analyses to account for the lower statistical power to 
detect effects of rare variants. We considered for follow-up all “NVs ǁith MAF ш Ϭ.Ϭϭ%, INFO > Ϭ.ϭ 
and P < 1x10
-5
 for any of the three BP traits. 
7. Loci assignment and classification 
SNVs achieving the lookup threshold from both the UK Biobank GWAS and exome discovery efforts 
were combined with the previously reported BP associated SNVs at the time of analysis to identify all 
variants in LD, referred to as the LD-lookup SNVs. We define a locus according to both an LD 
threshold of r
2
 ш Ϭ.Ϯ aŶd a ϭMď iŶteƌǀal ƌegioŶ. HeŶĐe ǀaƌiaŶts ƌeaĐhiŶg aŶ ƌ2 ш Ϭ.Ϯ thƌeshold ǁithiŶ 
500kb downstream and upstream of the LD-lookup SNVs were identified and assigned to loci sets. A 
locus set is composed of all SNVs linked by LD regardless of their association P-value and whether 
previously reported or not. For example, if SNV A is in LD with SNV B, and SNV B is in LD with SNV C, 
but SNV A and C are not in direct LD; SNV A, B and C would be part of the same locus set as SNV B is 
in LD with both A and C. The loci were then classified into three different types: (i) non-significant 
previously reported locus, if it contained at least one SNV from the set of previously reported-LD 
variants for previously reported variants at the time of analysis, but did not reach any of the lookup 
thresholds so was not contained in the list of SNVs for replication, (ii) UK Biobank-GWAS locus, if it 
contained at least one SNV reaching the lookup criteria threshold from the GWAS discovery, (iii) UK 
Biobank-exome locus, otherwise, containing SNVs which exclusively came from the UK Biobank-
exome discovery lookups and are not in LD with any of the GWAS discovery lookups and are 
therefore not contained in a UK Biobank-GWAS locus. All UK Biobank GWAS and exome top-loci 
were screened to check for the presence of previously reported LD variants, to distinguish our 
discovery loci from previously reported BP loci at the time of analysis. From here onwards, we use 
the ǁoƌd ͞Ŷoǀel͟ to distiŶguish fƌoŵ aŶǇthiŶg ǁhiĐh had ďeeŶ pƌeǀiouslǇ ƌepoƌted at the tiŵe of 
analysis, aŶd ͞pƌeǀiouslǇ ƌepoƌted͟ ƌefeƌs to all kŶoǁŶ ǀaƌiaŶts that had ďeeŶ ƌepoƌted aŶd 
validated at the time of analysis. 
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A second stage of loci assignment was performed on the novel and previously reported loci to 
identify potential secondary signals within these loci. Each novel locus was reduced only to the set of 
SNVs which met the lookup criteria thresholds, and these remaining SNVs were reassigned to new 
locus subsets by r
2
 ш Ϭ.Ϯ, aŶd deŶoted as sigŶals. This alloǁs the paƌtitioŶiŶg of loĐi iŶto sepaƌate, 
independent signals, not in direct LD with each other, i.e. some loci may have multiple pairwise-
independent (r
2
 < 0.2) signals within a 1Mb region. Similarly, in order to identify potential secondary 
signals in the previously reported loci, each locus was reduced to the variants in LD meeting the 
lookup thresholds, and these variants were reassigned to new locus subsets. All subsets which 
contained at least one variant in direct LD with the previously reported SNVs were removed, leaving 
the remaining subsets as potential secondary signals. If validated, these potential secondary signals 
at novel and previously reported loci could then be subsequently tested for statistical independence 
by conditional analysis.  
These final sets, novel and previously reported, are referred to as the discovery association signals. 
For each discovery association signal we identified the most significantly associated SNV within the 
set, with minimum P-value across all three BP traits, and refer to this as the sentinel SNV. Similarly, 
for any novel loci containing multiple signals within the 1Mb locus region, the sentinel signal was 
identified as the most significant SNV. 
All SNVs within the loci were mapped to genes (GRCh37.75) when the variant localized within 5kb of 
the staƌt oƌ eŶd of the geŶe͛s tƌaŶsĐƌiptioŶ ;ďedtools ǀϮ.ϭϳͿ.  Any genes which were annotated from 
previously reported-LD variants were listed, and referred to as previously reported BP genes 
(Supplementary Table 2). 
A signal was classified as secondary within a previously reported region if it satisfied at least one of 
the following conditions: i) it is a secondary signal from a locus that contains at least one previously 
reported-LD ǀaƌiaŶt ;as aďoǀeͿ, iiͿ at least oŶe of the “NVs ǁithiŶ the sigŶal͛s ĐoƌƌespoŶdiŶg loĐus 
maps to a previously reported BP gene or feature (Supplementary Table 30), such as long non-
coding RNA, pseudogenes, or long non-coding transcripts, iii) the sentinel SNV is within 500kb of a 
previously reported BP-associated SNV, or iv) the signal is within the HLA region (chr 6: 25–34 Mb) as 
for simplicity, due to the complicated LD structure, we treat the entire HLA region as a previously 
reported BP region.  
All other signals are classified as not previously reported at the time of analysis, in order to be 
followed-up as potential novel loci. 
8. Selection of variants for follow-up 
For the primary discovery analysis, the sentinel signal SNV at each novel locus was considered for 
validation and then any other validated SNV signals within the 1Mb locus region were considered as 
potential secondary signals for conditional analysis investigation. 
Due to the slightly different coverage from the imputation strategies and reference panels used by 
ICBP-1000G and UK Biobank, the list of UK Biobank-GWAS lookup signals was cross-referenced with 
the list of SNVs available within the ICBP-1000G data, in order to check that any SNVs selected for 
follow-up were covered within ICBP-1000G for possible replication. Of the total 235 SNVs selected 
for replication, 218 were covered within ICBP-1000G data, either directly or by proxies, or with an 
alternative SNV available within the locus. The proxies were in high LD with the sentinel SNV (r
2
 > 
0.8; using LD calculated within UK Biobank), for which the proxy with the highest r
2
, then closest 
position to the sentinel SNV was selected. For loci where the sentinel SNV was not covered either 
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directly or by a proxy, the most significantly associated SNV across all BP traits with P < 1x10
-6
 within 
the LD set, which was covered within ICBP-1000G data, was selected as the alternative SNV. Only 17 
loci could not be followed-up, due to a lack of coverage in the replication resources (Supplementary 
Table 29). However, most of these signals were sets containing only a few associated SNVs, including 
ŵaŶǇ ͚siŶgletoŶs͛ ǁith oŶlǇ oŶe “NV ǁithiŶ the LD set at the P < 1x10-6 lookup threshold, and 
therefore less likely to be covered in ICBP-1000G, and perhaps more likely to be potential spurious 
findings. We further checked that each SNV selected for follow-up had concordant single nucleotide 
polymorphism (SNP) vs Indel status in both UK Biobank and ICBP-1000G. Similarly, of the 54 
previously reported BP loci containing potential secondary SNVs, 51 loci could be followed-up with 
the potential secondary SNVs covered within ICBP-1000G data. In summary, a total of 218 SNVs from 
the GWAS discovery association signals were requested for lookups. 
9. Replication datasets 
The following studies contributed to the replication of the UK Biobank-GWAS lookups. More 
information on the individual cohorts can be found within Supplementary Table 3 (study 
characteristics, summary descriptives, genetic data information and quality control applied): 
ICBP-1000G: The International Consortium for Blood Pressure GWAS 1000G analyses. 
The individual studies who contributed to the ICBP-1000G discovery analyses are listed below: 
AGES: Age, gene/Enviroment Susceptibility-Reykjavik Study  
ARIC: Atherosclerosis Risk in Communities  
ASPS: Austrian Stroke Prevention Study  
B58C: British 1958 birth cohort  
BHS: Busselton Health Study  
CHS: Cardiovascular Health Study  
COLAUS: Cohorte Lausannoise  
COROGENE: Genetic Predisposition of Coronary Heart Disease in Patients Verified with Coronary 
Angiogram (controls for this study are a part of the National FINRISK Studies)  
CROATIA-Korcula: CROATIA-Korcula  
CROATIA-Split: CROATIA-Split  
CROATIA-Vis: CROATIA-Vis  
EGCUT: Estonian Genome Center  
EGCUT2: Estonian Genome Center  
EPIC: European Prospective Investigation in Cancer and Nutrition 
ERF: Erasmus Rucphen Family  
Fenland Fenland Study  
FHS: Framingham Heart Study 
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FINNRISK CASE: Predicting CVD in FINRISK cohorts, cases 
FINRISK_ctrl: Predicting CVD in FINRISK cohorts, controls 
FUSION: Finland-United States Investigation of NIDDM Genetics Study  
GRAPHIC: Genetic Regulation of Ambulatory Blood Pressure in the Community 
H2000: Health 2000 controls 
Health ABC The Health Aging and Body Composition Study  
HTO  
INGI_VB: Italian Network of Genetic Isolates - Val Borbera 
INGI-Cilento: Italian Network on Genetic Isolates - Carlantino Project  
INGI-FVG: Genetic Park of Cilento and Vallo di Diano Project 
INIG-CARL: Italian Network on Genetic Isolates - Friuli Venezia Giulia Genetic Park 
IPM: Charles R. Bronfman Institute for Personalized Medicine (IPM) BioBank Genome Wide 
Association Study of Cardiovascular, Renal and Metabolic Phenotypes 
KORAS3: Kooperative Gesundheitsforschung in der Region Augsburg  
KORAS4: Cooperative Health Research in the Region of Augsburg (Survey 4)  
LBC1921: Lothian Birth Cohort 1921  
LBC1921: Lothian Birth Cohort 1936  
LOLIPOP_EW610: London Life Sciences Prospective Population Study 
MESA: Multi-Ethnic Study of Atherosclerosis  
MICROS: MICROS  
MIGen: Myocardial Infarction Genetics Consortium  
NESDA: Netherlands Study of Depression and Anxiety  
NSPHS: The Northern Sweden Population Health Study  
NTR: Netherlands Twin Register  
ORCADES: Orkney Complex Disease Study  
PHASE: Prospective Investigation of the Vasculature in Uppsala Seniors  
PIVUS: Precocious Coronary Artery Disease  
PROCARDIS: PHArmacogenetic Study of Statins in the Elderly at risk  
RSI: Rotterdam Study 1  
RSII: Rotterdam Study 2  
RSIII: Rotterdam Study 3  
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SHIP: Study of Health in Pomerania  
STR: Swedish Twin Register  
TRAILS: Tracking Adolescents' Individual Live Surveys  
TRAILS-CC: Tracking Adolescents' Individual Live Surveys - Clinical Cohort 
ULSAM: Uppsala Longitudinal Study of Adult Men  
WGHS: Women's Genome Health Study YFS The Young Finns Study  
YFS: The Young Finns Study 
ASCOT
6
: The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) includes (19,342 hypertensives) 
enrolled in a randomised controlled trial of calcium channel blocker based regimen or a beta-blocker 
based regimen with blood pressure greater than 140/90 mm Hg on treatment of 160/100 mm Hg off 
treatment and followed for 5.5 years. Only a subset of the participants consented to DNA extraction 
for genetic studies. Data was genotyped separately for patients from UK/Ireland (ASCOT-UK: N = 
3,803) and Scandinavia (ASCOT-SC: N = 2,462). 
BRIGHT
7
: The MRC British Genetics of Hypertension study (2,001 hypertensives) included white 
European individuals with hypertension drawn from the upper 5% of the blood pressure distribution 
and usually on treatment subjected to GWAS. 
EGCUT
8
: The Estonian Biobank is the population-based biobank of the Estonian Genome Center of 
the University of Tartu (EGCUT). The project is conducted according to the Estonian Gene Research 
Act and all participants have signed broad informed consent. The cohort size is currently 51,535 
people from 18 years of age and up. All subjects are volunteers and were recruited randomly by 
general practitioners (GP) and physicians in hospitals. A Computer Assisted Personal Interview is 
ĐoŶduĐted at the doĐtoƌ͛s offiĐe to ƌeĐoƌd peƌsoŶal data ;plaĐe of ďiƌth, plaĐe;sͿ of liǀiŶg, ŶatioŶalitǇ 
etc.), genealogical data (family history spanning four generations), educational and occupational 
history, lifestyle data (physical activity, dietary habits – food frequency questionnaire, smoking, 
alĐohol ĐoŶsuŵptioŶ, ǁoŵeŶ͛s health, ƋualitǇ of lifeͿ. The EGCUT dataďase has ďeeŶ liŶked ǁith the 
national registries and hospital databases for obtaining up-to-date phenotypic information, including 
but not limiting to Death Registry, Health Insurance Registry and epicrisis from major hospitals. 
Medical history and current health status are recorded according to the ICD10, medication according 
to the ATC. Anthropometric measurements, blood pressure (sitting position at the end of the 
interview), and resting heart rate are measured; 30-50 mL of venous blood are collected into EDTA 
Vacutainers. These aƌe tƌaŶspoƌted to the ĐeŶtƌal laďoƌatoƌǇ of the EGCUT at +ϰ…+ϲ 0C (in 6 to 36h) 
where DNA, plasma and WBC are immediately isolated and kept in aliquots in MAPI straws in liquid 
N2. All procedures are run according to ISO 9000-2008 (www.biobank.ee) 
GenScot
9
: Generation Scotland: Scottish Family Health Study (GS:SFHS) is a family-based genetic 
epidemiology study of ~24,000 volunteers from ~7000 families across Scotland with the capacity for 
follow-up through record linkage and re-contact. Participants completed a demographic, health and 
lifestyle questionnaire and provided biological samples including DNA, and ~21,500 participants 
underwent detailed clinical assessment, including anthropometric, cardiovascular, respiratory, 
cognition and mental health (http://www.ed.ac.uk/generation-scotland). 
Lifelines
10
: This is a multi-disciplinary prospective population-based cohort study examining in a 
unique three-generation design the health and health-related behaviours of 165,000 persons living 
in the North East region of The Netherlands. It employs a broad range of investigative procedures in 
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assessing the biomedical, socio-demographic, behavioural, physical and psychological factors which 
contribute to the health and disease of the general population, with a special focus on 
multimorbidity and complex genetics. Details of the protocol have been described elsewhere 
(https://www.lifelines.nl/lifelines-research/news).  
PREVEND
11
: The Prevention of REnal and Vascular ENd-stage Disease (PREVEND) study is an ongoing 
prospective population-based study of individuals from the Netherlands, investigating the natural 
course of increased levels of urinary albumin excretion and its relation to renal and cardiovascular 
disease. Further details are available on the study website: www.prevend.org. 
 
The following consortia contributed to the replication of the UK Biobank exome lookups: 
European exome consortium
12
: Consortium comprises 51 studies from various European countries 
within 3 contributing consortia (CHD exome+ consortium, ExomeBP consortium, T2D-
GENES/GoT2DGenes consortium). Samples from all studies were genotyped using a version of the 
Illumina exome array. Central QC was performed to identify studies with QC issues and remove 
variants failing quality thresholds. 3 quantitative traits were analysed (DBP, SBP, PP) with and 
without applying inverse rank normalisation, and HTN was analysed as a binary trait. The 51 
contributing studies are: Airwave, ASCOT_SC, ASCOT_UK, 1958BC, BRIGHT_CASES, 
BRIGHT_CONTROLS, CROATIA-Korcula, DIABNORD, EGCUT, FENLAND, FINRISK97/02, GS:SFHS, 
GLACIER_Controls, GODARTS_diab, GODARTS_nondiab, GRAPHIC, HELICMANOLIS, HUNT, INCIPE, 
LBC1921, LBC1936, LIFELINES, MDC, Northern Finland Birth Cohorts 1966 and 1986, OBB, 
PIVUS/ULSAM, TwinsUK, UHP, UKHLS, ADDITION, DPS, DR'S EXTRA Study, FIN-D2D 2007, FINRISK 
2007, FUSION, Health 2006/2008, Inter99, PPP, SDC, SDR/ANDIS, VejleCases, VejleCtrl, CCHS, CGPS, 
CIHDS, EPIC-CVD, EPIC-InterAct, MORGAM, PROSPER, WOSCOPS. 
CHARGE BP exome consortium
13
: The CHARGE BP exome Consortium includes 16 studies from the 
CHARGE+ consortium including a total of 146,562 samples, of which N=120,473 are European 
ancestry. Samples from all studies were genotyped using Illumina Infinium Human Exome Array (v 
1.0 or 1.1). QC was performed either centrally (10 studies) or by individual cohorts (6 studies) to 
identify studies with QC issues and remove variants failing quality thresholds. Four quantitative traits 
(DBP, SBP, mean arterial pressure, pulse pressure) were analysed with and without applying inverse 
rank normalisation. Hypertension was analysed as a binary trait. The 16 contributing studies are: 
AGES, ARIC, BioVU, CARDIA, CHS, FamHS, FHS, Health ABC, HRS, JHS, MESA, Mt. Sinai, Rotterdam 
“tudǇ, “HIP, WGH“, WoŵeŶ͛s Health IŶitiatiǀe. 
10. Meta-analyses 
The UK Biobank-GWAS replication meta-analysis combined the ICBP-1000G meta-analysis data with 
the lookup results from the seven other replication studies. As the ICBP-1000G data had been 
generated from a large meta-analysis of many studies, N-effective was provided, calculated as the 
product of the sample size and imputation quality per SNV within each study and summed over the 
whole ICBP-1000G meta-analysis. We therefore used N-effective as the input N for ICBP-1000G 
within METAL. For the seven individual studies, to take account of imputation quality and apply 
further QC prior to analysis, SNVs with imputation quality < 0.3 were excluded from the meta-
analysis input, and sample size N was used for all remaining SNVs. Allele frequencies and strand 
alignments were tracked for consistency within the meta-analysis. For consistency with the SNVs 
present in the replication data sets, the results for the proxy SNVs were used within the UK Biobank 
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discovery input for the variants that required proxies or alternative SNVs to the sentinel SNVs for the 
UK Biobank-GWAS lookups. Overall, sentinel and proxy SNVs had similar levels of association in the 
UK Biobank-BP discovery analysis (Supplementary Table 28). Genomic control (GC) had already been 
applied to the ICBP-1000G meta-analysis and their post-GC results were used as the input into our 
meta-analysis. No further GC corrections were applied in METAL for our UK Biobank-GWAS 
replication or combined meta-analyses. 
The UK Biobank-exome meta-analysis synthesized meta-analysis data of individuals of European 
ancestry from two BP exome consortia (European exome consortium and CHARGE BP exome 
consortium) for the lookup variants. As in the GWAS analysis the allele frequencies and strand 
alignments were tracked for consistency within the meta-analysis.  
11. Significance thresholds 
We note that the standard genome-wide significance threshold (P < 5 x 10
-8
) is suitable for validation 
from our combined meta-analysis. The UK Biobank-GWAS analysis follows up 9.8 million SNVs with 
MAF ш 1% and coverage in 1000G data, while recent simulations in the literature14 suggest a similar 
significance threshold of P < 3×10
-8
 based on denser Whole-Genome Sequencing (WGS) studies 
filteƌed at MAF ш ϭ% ǁith aŶ LD-independence r2 threshold of 0.8. In addition, we require replication 
support of P < 0.01 which is more stringent than a range of thresholds calculated according to False 
Discovery Rate (FDR) which gives FDR thresholds of 0.03 < P < 0.04 using the approaches proposed 
by Benjamini and Hochberg 
15
and Benjamini and Yekutieli
16
 respectively. As a further protection 
against false positive findings, we require concordance in direction of effect between the discovery 
and replication resources.  
12. Conditional analyses  
Within the novel loci containing potential secondary validated SNVs within the 1Mb locus region, i.e. 
in addition to the sentinel SNV, conditional analysis was performed, conditioning on the sentinel 
SNV, to test for independence of the secondary SNV according to a 1.5 fold threshold for reduction 
in P-value, with adjustment for covariates as in the discovery GWAS. For validated novel loci with 
more than one secondary SNV, conditional analysis results were considered for all pairwise 
combinations of SNVs within the locus, sequentially in order of main discovery association 
significance, to conclude with a set of pairwise conditionally independent SNV association signals. 
For previously reported loci at the time of analysis, each validated secondary known signal is 
matched to its corresponding locus according to the criteria which defined it as a secondary signal at 
that locus, i.e. either (i) the locus that it was partitioned from during the annotation pipeline, (ii) 
matching according to the annotated gene in common, or (iii) the locus containing the previously 
reported SNV which is within 500kb. As noted above, signals within the HLA region were excluded 
from further conditional analysis. For each of these loci the previously reported SNV(s) within the 
region are listed (Supplementary Table 13). Within SNPTEST, a conditional analysis is run for each 
previously reported region containing a validated secondary signal, allowing the region of analysis to 
cover both the previously reported locus and the secondary signal.  
Further rounds of conditional analysis are performed for regions containing more than one 
independent validated secondary signal. The secondary signals are ordered by significance according 
to the UK Biobank discovery association P-values for their validated BP trait, and a second round of 
analysis then conditions further on the most associated secondary signal as well as the sentinel SNV 
12 
 
to assess whether any further SNVs pass the 1.5 fold threshold test of independence. This iterative 
conditioning process continues until no remaining secondary SNVs pass the conditional test. 
13. Lookups in non-European ancestries 
The following consortia and studies contributed to the non-European ancestry lookups: 
iGEN-BP
17
: The International Genomics of Blood Pressure Consortium (iGEN-BP) genome-wide 
association was analyzed in a total of 31,516 individuals of East Asian ancestry and 33,126 of South 
Asian ancestry. Imputation was carried out using haplotypes from HapMap Phase 2. Quality control 
checks included on the distribution of effect sizes across phenotypes and comparison of allele 
frequencies against those expected from HapMap populations. There were between 2,127,883 (SBP) 
and 2,166,286 (hypertension) SNPs for analysis after quality control. Associations of SNPs with 
phenotype were tested in each cohort separately in single-marker tests, using regression analysis 
and an additive genetic model. Principal components and other study-specific factors were included 
as covariates to account for population substructure. Test statistics from each cohort were then 
corrected for their respective genomic control inflation factor to adjust for residual population 
substructure. SNPs with information score <0.5 and minor allele frequency (MAF) <1% (weighted 
average across the cohorts) as well as sample size <50% of the maximum n for the phenotype were 
removed. SNPs showing heterogeneity of effect (P_het < 1 × 10
−8
) were also removed. The 23 studies 
contributing to the East Asian ancestry meta-analysis are: AASC, CAGE-Amagasaki, CAGE_GWAS1, 
CAGE-KING_Ommi, CAGE-KING_Quad, CLHNS, GenSalt, KARE, NHAPC, SCES, SiMES, SP2-1m, SP2-
550, SP2-610, SRS_Cases, SRS_Controls, TWSC, Vanderbilt_birdsuite, Vanderbilt_panscan, 
Vanderbilt_CRC_GWAS (SHANGHAI1), Vanderbilt_CRC_GWAS (SHANGHAI2), Vanderbilt_upperGI 
(SMHS), Vanderbilt_upperGI (SWHS). The 13 studies contributing to the South Asian ancestry meta-
analysis are: AIDHS/SDS_Cases, AIDHS/SDS_Controls, LOLIPOP_IA300, LOLIPOP_IA610_Cases, 
LOLIPOP_IA610_Controls, LOLIPOP_IAP, PROMIS_GWAS1_Cases, PROMIS_GWAS1_Controls, 
PROMIS_GWAS2_Cases, PROMIS_GWAS2_Controls, RHS, RHS_610K, SINDI. 
The CHD exome+ consortium
18
 contributed South Asian samples from two studies: N=5,756 
individuals from BRAVE (Bangladesh Risk of Acute Vascular Events study) and N=22,094 individuals 
from PROMIS (Pakistan Risk of Myocardial Infarction Study; 
http://www.phpc.cam.ac.uk/ceu/research/promis/). 
CHARGE BP exome consortium
13
: The CHARGE BP Exome Consortium also contributed samples of 
African (N=21,503) and Hispanic (N=4,586) ancestry. 
Note: Only SNVs available in at least 60% of the samples within each study were considered within 
the non-European lookup analyses. 
14. Airwave Study data 
The Airwave Health Monitoring Study (Airwave)
19
 was used as an independent cohort for risk score 
analyses (see Methods Online) and for analysis of metabolomics data. The Airwave analyses included 
14,002 participants with imputed genetic data.  Systolic and diastolic blood pressures were 
measured as three consecutive readings using a digital blood pressure monitor (Omron HEM 705-CP 
digital BP monitor). Mean SBP and DBP adjusted for medication (as previously defined) were 
calculated from available readings and were used as dependent variables in the analyses.  
Genetic risk scores (GRS) were constructed from a combination of both previously reported variants 
at the time of analysis, and validated SNVs from our study. Genetic dosages were extracted from the 
13 
 
Airwave 1000G imputed data, extending to proxies (r
2
 > 0.8) if required. The previously reported BP 
variants were filtered by LD (r
2
 of 0.2) and of the remaining 152 independent SNVs, 144 SNVs were 
covered exactly, and proxies were available for another 2 SNVs, providing a total of 146 pairwise-
independent SNVs. All the 115 validated novel variants were available in the Airwave data. Weights 
were applied to all previously reported and novel SNVs in the GRS, as described in the Online 
Methods and in Supplementary Table 22. 
From the Airwave plasma 
1
H NMR metabolomics dataset measured using MRC-NIHR National 
Phenome Centre protocols, we undertook a lipoprotein subclass analysis using a regression-based 
prediction of lipid concentrations to characterise lipids (cholesterol, free cholesterol, phospholipids 
and triglycerides) and apolipoproteins (Apo-A1, ApoA2 and Apo-B) for VLDL, IDL, LDL and HDL 
classes, as well as six subclasses of VLDL and LDL and four subclasses HDL (data provided by Brucker 
Biospin GmbH, Rheinstetten Germany 
20
). Overall, 105 different lipoprotein subclasses were 
generated from the deconvolution the CH3-group signal of the lipoproteins at 0.8ppm. 
(Supplementary Table 20). 
15. Cardiovascular outcomes data in UK Biobank 
To classify cardiovascular disease (CVD) outcomes we used self-reported baseline information on 
CVD prevalence available in UKB, and linkage to Hospital Episodes Statistics (HES) and mortality data. 
HES provide detailed information for participants admitted to hospital and includes coded data on 
diagnoses and operations. Coronary artery disease, stroke and peripheral artery disease were 
classified using International Classification of Disease (ICD) 9 and 10 codes and operation codes 
(Supplementary Table 25). The large UK Biobank cohort with sufficient numbers of cardiovascular 
events enables the assessment of cardiovascular risk within the same data set, noting that results 
are still independent, as the variants within the GRS are selected for their association with BP, not 
for cardiovascular outcomes.  
16. Functional analyses 
A structured approach was used to identify candidate regulatory variants, using two sources of 
regulatory information for annotation: ENCODE annotated DNase I sites in 123 cell types 
(wgEncodeAǁgDŶaseMasteƌ“itesͿ aŶd a ƌefeƌeŶĐe data set of oǀeƌ ϯ ŵillioŶ DNase ͞footpƌiŶt 
ǀaƌiaŶts͟. FootpƌiŶt ǀaƌiaŶts ǁeƌe defiŶed ďǇ MoǇeƌďƌaileaŶ et al, ;ϮϬϭϲͿ21  from a set of functional 
regulatory regions that integrate sequence position weight matrices with ENCODE and NIH Roadmap 
DNase I footprinting data to predict the impact of a sequence change on transcription factor binding 
in a panel of 650 cell-types. All variants in LD (r
2
 ш Ϭ.ϴͿ ǁith the seŶtiŶel “NV ǁeƌe ƌeǀieǁed aŶd the 
variant with the lowest imputed P-value (for the same trait association as the sentinel) overlapping a 
DNase site was selected as the best regulatory candidate in each locus. 
Hi-C analyses: Since SNVs in intergenic regulatory regions may act through long-range promoter-
enhancer/silencer chromatin interactions, we aim to identify distant target genes of SNVs using 
chromatin folding data. Chromatin interaction can be assayed with the Hi-C technique, which 
identifies interacting genomic regions from the number of paired-end sequence reads that connect 
two genomic regions after crosslinking the cells, digesting the genome with a restriction enzyme and 
ligating fragment ends that are held together by 3D chromatin interactions. The 3D folding of the 
genome is tissue specific, therefore In order to identify potential target genes of SNVs, we used a cell 
type relevant to the BP phenotype, human umbilical vein endothelial cells (HUVEC)
22
.   
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To find regulatory loops, from our validated GWAS loci, we took the location of either the sentinel 
SNV, if it was in a DNaseI hypersensitivity site (DHS), or the next most significant SNV for the same 
trait within a DHS and therefore potentially a regulatory SNV. Then using 5kb resolution HUVEC Hi-C 
data, taking only reads MAPQ>30, we identified the strongest SNV interacting regions after 
Knight&Ruiz (KR) normalisation of interaction strength and distance normalization. Taking the 
strongest interaction where the interacting region overlapped with a promoter region, as annotated 
by the ChIPseeker R package, we defined the potential target genes of these regulatory SNVs.  
Enrichment testing: In order to distinguish enrichment of the validated variants from our study 
against the previously reported variants at the time of analysis, we performed two sets of 
enrichment analyses. The first only included our validated SNVs and their proxies in high LD (r
2 ш Ϭ.ϴͿ 
(Tables 1-3), and the second investigated all SNVs together (SNVs validated in our study, previously 
reported variants at the time of analysis, and secondary SNVs) and their proxies in high LD (r
2 ш Ϭ.ϴͿ. 
The two analyses allow us to identify properties of our findings as well as highlighting mechanisms 
(e.g. pathways, tissues, cells, etc.) for all BP-associated variants.  
FORGE
23
 analysis: FORGE compares the frequency of query SNVs in different cell types with a 
reference set of 1204 control SNVs from the NHGRI GWAS catalog with discovery P-values < 5 × 10
−8
 
in European ancestry populations. For each cell-type and P-value threshold, the enrichment of query 
SNVs mapping to footprints is expressed as a P-value derived from a logistic mixed effect model.   
GenomeRunner
24
 analysis of histone marks: GenomeRunner tests whether co-localization of a set of 
BP-associated SNVs with genome annotation features is significantly different from what would be 
expected by chance for a similar sized random set of SNVs. Tracks of histone modifications obtained 
by ChIP-seq from ENCODE were used for the assessment of histone marks, and significant 
enrichment of histone marks was investigated in a wide range of cell types. We also tested for cell 
type specificity of enrichments of SNV sets, which compares whether a cell type-specific enrichment 
is significantly different from the overall enrichment of a SNV set. 
Fantom5
25
 analysis of tissue clustering: Cardiovascular relevant tissue expression was investigated, 
using Fantom5 reference transcript expression data (fantom.gsc.riken.jp/5).  Kmeans clustering was 
performed on BP-associated genes at our validated loci with Gene Cluster 3.0
26
 using a Euclidean 
distance similarity matrix and K=5. Clusters were visualized using Java Treeview
27
. 
17. Experimental studies 
Gene expression associated with sentinel SNVs in SF3A3, ADAMTS7, NOX4 was tested using vascular 
smooth muscle cells (VSMCs) and endothelial cells (ECs) isolated from human umbilical cord artery 
and vein (Royal London hospital, UK) respectively according to established protocol
28
, and approved 
by the appropriate local ethics committee (08/H0704/140). VSMCs and ECs were harvested from 
flasks and suspended in ϱϬϬμL lysis buffer (10 mM Tris PH 8.0, 10 mmol/L EDTA, 100 mmol/L NaCI, 
0.5 % w/v SDS), and were then administered ϮϱϬμL 5mmol/L NaCI. The mixture was centrifuged at 
12,000g for 5min and the supernatant transferred to a fresh eppendorf then ϱϬϬμL isopropanol 
added. The DNA pellet was collected and washed with ϱϬϬμL 70% ethanol, then resolved in ϰϬμL 
nuclear free water. The concentration of DNA was quantified by NanoDrop and adjusted to 5ng/µL 
for further genotyping. The Kbiosciences Competitive Allelic-specific PCR SNP genotyping system 
(KASPar; LGC Genomics Kbiosciences) was used for genotyping according to product introductions. 
Primers targeting the allelic specific DNA amplification were designed by Primer-Picker 
(Kbiosciences) (Supplementary Table 31). 10ng DNA from each sample plus the master mix was 
plated in a 384-well plate and subjected to PCR (ABI 7900HT machine).  
15 
 
Total RNA was extracted from human VSMCs and ECs, using the SV total RNA isolation system 
(Promega), then reverse transcribed into complementary DNA (cDNA) with the ImProm-IITM 
‘eǀeƌse TƌaŶsĐƌiptioŶ “Ǉsteŵ ;PƌoŵegaͿ aĐĐoƌdiŶg to ŵaŶufaĐtuƌeƌ͛s iŶstƌuĐtioŶs. Ƌ‘T-PCR for 
SF3A3, ADAMTS7, NOX4 and 18S (internal control) was performed on cDNA in duplicate by using 
Power Up SYBR® Green PCR Master Mix kit (Life Technologies) according to the product guide using 
real-time quantitative PCR instrument (ABI 7900HT machine). Three pairs of primers were designed 
(Supplementary Table 31) and tested specificity and only primer pairs that had good specificity were 
chosen for the qPCR. The expression levels of SF3A3, ADAMTS7 and NOX4 relative to 18S from 
independently repeated experiments were then determined by the 2
-ΔΔCt
 method
29
. 
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Supplementary Figure 1: Functional analyses schematic for the functional annotation and prioritisation of GWAS 
associated variants and genes. SNVs: single nucleotide variants; LD: Linkage Disequilibrium; eQTL: expression 
Quantitative Trait Loci; UCSC: University of California Santa Cruz (UCSC) genome browser; IPA: Ingenuity Pathway 
Analysis (IPA) software (IPA®,QIAGEN Redwood City,www.qiagen.com/ingenuity); DEPICT: Data-driven Expression 
Prioritized Integration for Complex Traits; GREAT: Genomic Regions Enrichment of Annotations Tool. 
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Supplementary Figure 2: UK Biobank GWAS discovery circos Manhattan plots (a), (b) and (c) for systolic blood 
pressure (SBP), diastolic blood pressure (DBP) and pulse pressure (PP) respectively. P-value results are plotted on a –
log10 scale (see legend) for all ~9.8 million variants with Minor Allele Frequency (MAF) ≥ 1% and imputation quality 
INFO > 0.1 analysed within the GWAS discovery. Associations are plotted in red for all variants within the 107 
validated loci from our study, in black for variants within unreported loci at the time of our analysis which were 
looked-up (P<1×10-6) in replication data but did not replicate, in blue for all variants within blood pressure loci that 
were previously reported at the time of our analysis, and grey otherwise. Loci names labelled around the edge are 
specific to each blood pressure trait, with red labels corresponding to loci validated in our analysis for the given trait 
(102 validated loci from Tables 1- 3 in total across all three plots from GWAS), and blue labels corresponding to 
previously reported loci at the time of analysis within which new independent secondary variants were identified (20 
GWAS variants in total from Supplementary Table 8b)  
 
(a) SBP 
 
(b) DBP 
 
(c) PP 
Supplementary Figure 3: Locus zoom plots of (a) 102 validated sentinel variants from UK Biobank GWAS discovery 
and (b) 5 validated sentinel variants from UK Biobank exome discovery. Linkage Disequilibrium is calculated within UK 
Biobank, with grey corresponding to r2 < 0.1. SBP: systolic blood pressure; DBP: diastolic blood pressure; PP: pulse 
pressure; MAF: Minor Allele Frequency; INFO: Imputation quality score from SNPTEST. 
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Supplementary Figure 4: Heat map of blood pressure associations using –log10(P-values) from the combined meta-
analysis. The rows of the heat map are the 107 sentinel validated SNVs from Tables 1-3  from both GWAS and exome 
discovery, ordered by trait, then by chromosome and genomic position base pairs. Red shows genomewide 
significance (P < 5x10-8), orange shows moderate significance (5x10-8 ч P < 0.01) and yellow shows no significant 
association (P ≥ 0.01). SBP: systolic BP; DBP: diastolic BP; PP: pulse pressure. 
Supplementary Figure 5: Association of blood pressure loci with other traits. Plot (a) shows results for associations 
with other traits which were extracted from the PhenoScanner database for the sentinel variants from Tables 1-3, 
including proxies in Linkage Disequilibrium (r2≥ 0.8), with genome-wide significant associations (P < 5×10-8). The loci 
are grouped by blood pressure traits ordered right to left according to the loci in Tables 1-3. There are four systolic 
blood pressure associated loci, 14 diastolic blood pressure associated loci and nine pulse pressure associated loci with 
associations with other traits reported in the literature. Traits are grouped into different disease categories: 
͞Pulse/HR͟ includes pulse, heart rate, pulse wave velocity and aortic stiffness traits; ͞CAD/CHD/MI͟: Coronary Artery 
Disease / Coronary Heart Disease / Myocardial Infarction; ͞Blood͟ traits: Haemoglobin levels and platelet counts; 
͞Lipids͟: LDL and Total Cholesterol; ͞BMI/WHR͟ includes Body Mass Index, weight, obesity, waist or hip 
circumference, Waist-Hip-Ratio; ͞MeŶarche͟: age at menarche; ͞LuŶg͟: lung function (FEV1); ͞Alzheiŵer’s͟ traits 
refers to Cerebrospinal fluid levels of Alzheiŵer’s disease related proteins; ͞CaŶcer͟ includes carcinomas, 
neuroblastomas, bladder cancer; ͞EducatioŶ͟: years of educational attainment. 
Plots (b) and (c) show mouse phenotype enrichment and disease ontology enrichment, respectively, of validated 
novel and previously reported variants. Enrichment was performed using the GREAT tool with the sentinel SNVs as 
query. 
 
 
Supplementary Figure 6: Results of previously reported variants at the time of analysis: comparison of UK Biobank 
(UKB) and originally published results. Plot (a) compares the Minor Allele Frequency (MAF) values in UK Biobank with 
those from the originally published studies, for all 163 previously reported blood pressure (BP) variants at the time of 
analysis. The plotted points are colour-coded according to the type of genetic association study that each variant was 
ideŶtified froŵ. For eǆaŵple, ͞GWAS͟ refers to staŶdard GeŶoŵe-Wide Association Studies in Europeans, whereas 
͞Other AŶcestries͟ refers to aŶalyses iŶ ŶoŶ-EuropeaŶs; ͞Bespoke chips͟ refers to e.g. studies usiŶg the CardioChip or 
MetaboChip; ͞Neǁ Methods͟ refers to aŶalyses usiŶg other ŵethodological strategies ǁhich ǁere Ŷot ŵaiŶ-effect 
associations, e.g. interaction analyses or multivariate analyses. Plot (b) compares the effect sizes for a subset of these 
previously reported variants, restricted to non-rare ǀariaŶts ;ϭ ǀariaŶt eǆcluded froŵ ͞Eǆoŵe-chip͟ ǁith MAF < ϭ% iŶ 
UKBͿ froŵ ŵaiŶ effect aŶalyses ;eǆcludiŶg ͞Neǁ Methods͟ categoryͿ of people of EuropeaŶ aŶcestry ;͞Other 
AŶcestries͟ category eǆcludedͿ. Three separate plots are proǀided for systolic ;SBPͿ, diastolic ;DBPͿ aŶd pulse 
pressure (PP) traits (hence any variants identified for hypertension or Mean Arterial Pressure are excluded), with 
effect sizes given in mmHg units. Each variant is plotted only once, for the primary BP trait that was originally 
reported. In each plot, the dotted line represents the Y=X line, and the r2 values report the statistical correlation 
between the UK Biobank and the published effect sizes. 
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(b) 
Supplementary Figure 7: Validated loci eQTLs across all tissues. The figure represents the number of validated loci 
from our study (total n=107) which contain at least one variant (in LD of r2 ≥ Ϭ.8 ǁith the seŶtiŶel SNVͿ ǁith aŶ eQTL 
association observed for each tissue type, according to the GTEx database. eQTL: expression quantitative trait loci ; 
LD linkage disequilibrium; SNV: single nucleotide variant; GTEx The Genotype-Tissue Expression project. 
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Supplementary Figure 8: In silico evidence supporting an eQTL in the SF3A3 gene. (A) UCSC (University of California 
SaŶta CruzͿ GeŶoŵe Broǁser ǀieǁ of the 3’ regioŶ of SF3A3. ENCODE (Encyclopedia of DNA Elements) Transcription 
factor Chip-Seq data shows widespread binding in the region of rs4360494, including the transcription Factor AP-2 
Alpha/Gamma B) GTEX Tibial Artery eQTL demonstrating decreased expression of SF3A3 in homozygous minor allele 
carriers. (C) G>C transversion removes predicted AP-2 binding. (eQTL: expression Quantitative Trait Locus) 
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Supplementary Figure 9: DEPICT tissue enrichment across all reported blood pressure associations  (both validated loci from 
our study,  and variants previously reported at the time of analysis). We find enrichment of expression across 31 tissues and 
cells, with highest enrichment found in arteries (P = 1.9×10-6; FDR < 0.01). Enrichment association passing false discovery 
testing is indicated in red. Figures: (a) Physiological systems tissue enrichment; (b) Tissue enrichment; (c) Cardiovascular system 
enrichment; (d) Endocrine system enrichment. Figures (c) and (d) are detailed subsections for tissues of interest taken from 
figure (a). DEPICT: Data-driven Expression Prioritized Integration for Complex Traits; FDR: False discovery rate. 
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Supplementary Figure 10: FORGE results. Sentinel variants for association with blood pressure are investigated for 
enrichment in ENCODE (Encyclopedia of DNA Elements) DNase I regulatory regions using FORGE. (a) FORGE DNase I 
sensitive region enrichment for all reported sentinel variants (both validated variants from our study, and variants 
previously reported at the time of analysis). Strongest enrichment is seen in vasculature (MVEC, Microvascular 
Endothelium) and highly vascularised tissues. Tissues in red are significant after correction for false discovery. (b) To 
further investigate the regulatory basis of the associated loci, candidate regulatory variants are selected for (b) 107 
validated loci from our study and (c) all reported loci (both 107 validated loci from our study, and previously reported 
loci at the time of analysis). Again enrichment is seen for vascular tissue especially vascular smooth muscle and 
endothelial cell types.  
(a) 
(b) 
(c) 
Supplementary Figure 11: Genome-wide enrichment of histone methylation marks among all reported sentinel 
variants (from both the 107 validated loci from our study, and previously reported variants at the time of analysis) for 
association with blood pressure. Histone mark enrichment is investigated using GenomeRunner.    
Supplementary Figure 12: The expression of genes contained within the 107 validated loci is investigated using K-
means clustering in the fantom5 gene expression reference data set, focusing on cardiovascular relevant tissues that 
show evidence of enrichment in DEPICT (Data-driven Expression Prioritized Integration for Complex Traits) and 
FORGE analysis. With K-means set to 5 clusters, tissue specific clusters are apparent, including vascular smooth 
muscle cells (VSMC) and fibroblasts, endothelial cells (including probable endothelial cells in highly vascularised 
tissues), and a combined vascular cell cluster. Clusters are also apparent for cardiopulmonary genes. A further 65 
genes do not cluster within tissue groups (not shown) and 71 genes are not detected in the fantom5 data. Yellow 
indicates down-regulation, purple indicates up-regulation.  
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Supplementary Figure 13: Gene expression in human vascular smooth muscle cells (VSMCs) and endothelial cells 
(ECs) detected by quantitative Polymerase Chain Reaction (qPCR) with standardization to internal control of 18S. Dots 
represent individual samples from each genotype with numbers indicated. Data are analysed using the 2-ΔΔCt method, 
log transformed and shown as mean with error bars, Standard Error of the Mean (SEM) on left (VSMCs) and right 
(ECs) of each panel.  Differences are determined by one-way Analysis of Variance (ANOVA) with Bonferroni correction 
for multiple comparisons. In (a): the sentinel variant rs4360494 at the SF3A3 locus is significantly associated with 
expression of SF3A3 in cell type-specific manner, with the major C allele associated with increased expression of 
SF3A3 in human VSMCs, but no genetic difference in ECs. In (b): A similar cell-type specificity is shown for genetic 
effect of sentinel variant rs62012628 on ADAMTS7 expression, with a significantly lower expression level for the 
minor T allele in human VSMCs. In (c) the minor A allele of sentinel variant rs2289125 at NOX4 gene locus is 
significantly related with a lower NOX4 expression level in human ECs. 
Supplementary Figure 14: Relationship between allele frequency and effect size of blood pressure associated 
variants, comparing the 107 validated variants in our study  and the previously reported variants at the time of 
analysis. The MAF values and effect sizes, all taken from UK Biobank discovery results, are plotted according to the 
most significant trait in the UK Biobank discovery data for previously reported variants, and for the validated trait for 
all other ǀariaŶts. VariaŶts are colour coded accordiŶg to the type of ǀariaŶt ;see legeŶd: ͞Preǀiously reported͟ is at 
the tiŵe of aŶalysis;  ͞Ŷoǀel͟ refers to all ϭϬϳ ǀalidated loci iŶ our study, ŵaŶy of ǁhich ǁere ǀalidated for the first 
tiŵeͿ. Note that the ͞ǀalidated secoŶdary SNVs͟ are ǀalidated SNVs at ͞Ŷoǀel͟ loci ǁhich ǁere Ŷot iŶdepeŶdeŶt of 
the sentinel SNV after conditional analysis. SBP: systolic blood pressure; DBP: diastolic blood pressure; PP: pulse 
pressure; MAF: Minor Allele Frequency; SNV: single nucleotide variant. 
Supplementary Figure 15: Ethnicity clustering performed using PCA. PC1 is plotted against PC2 for all N~150,000 UK 
Biobank participants, colour-coded according to the five ethnic clusters created from our K-means PCA clustering, 
froŵ ǁhich oŶly ͞White͟ CaucasiaŶs are selected for aŶalysis of iŶdiǀiduals of EuropeaŶ aŶcestry. PCA: PriŶcipal 
Component Analysis; QC: Quality Control; PCs: Principal Components. 
Supplementary Figure 16: Quantile-Quantile plots of results for (A) systolic blood pressure (SBP) from UK Biobank 
GWAS, (B) diastolic blood pressure (DBP) from GWAS, (C) pulse pressure (PP) from GWAS, (D) SBP from UK Biobank 
exome, (E) DBP from exome and (F) PP from exome. The black curves are based on all the variants in the 
correspoŶdiŶg aŶalysis, ǁith ~ϵ.8 ŵillioŶ ǀariaŶts ǁith MiŶor Allele FreƋueŶcy ≥ ϭ% aŶd iŵputatioŶ Ƌuality INFO > Ϭ.ϭ 
for GWAS for plots (A-C) and ~150,000 exome variants for plots (D-F). The green curves are results after excluding 
previously reported blood pressure variants at the time of analysis and all variants in Linkage Disequilibrium with 
them (r2 ≥ Ϭ.2Ϳ. The geŶoŵic iŶflatioŶ factor, λ, is reported (NB: LD Score regression analysis yields λ~1.05 for each 
BP-GWAS, confirming that any inflation in the GWAS findings reflects polygenic influence on blood pressure). 
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